Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 07:00 ET
|
Cabaletta Bio
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track Designation in SLE and LN – – Strengthened balance sheet by closing $100M public offering extending cash...
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
July 24, 2023 08:00 ET
|
Cabaletta Bio
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE...
Cabaletta Bio to Present at the Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 31, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
May 22, 2023 16:30 ET
|
Cabaletta Bio
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first...
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
May 17, 2023 22:16 ET
|
Cabaletta Bio
PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first...
Cabaletta Bio Announces Proposed Public Offering of Common Stock
May 17, 2023 16:01 ET
|
Cabaletta Bio
PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first...
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
May 16, 2023 07:00 ET
|
Cabaletta Bio
– Phase 1/2 trial for CABA-201 planned to initiate in patients with myositis at an initial dose that is equivalent to the dose used in a patient with myositis as reported in the recent Lancet...
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 07:00 ET
|
Cabaletta Bio
– IND application cleared within 30 days for clinical trial of CABA-201 in patients with LN and SLE and Fast Track Designation granted by the FDA for CABA-201 to deplete CD19-positive B cells and...
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 02, 2023 16:35 ET
|
Cabaletta Bio
PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
May 01, 2023 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...